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Abstract
Objective:We aim to explain why salivary lactoferrin (Lf) levels are reduced in patients
sufferingmild cognitive impairment (MCI) and sporadic Alzheimer’s disease (sAD).1 We
also will discuss if such Lf decrease could be due to a downregulation of the sAD associ-
ated systemic immunity.
Background: Several non-neurological alterations have been described in sAD, mainly
in skin, blood cell, and immunological capacities. We reviewed briefly the main patho-
physiological theories of sAD (amyloid cascade, tau, unfolder protein tau, and amyloid
deposits) emphasizing themost brainbasedhypotheses suchas theupdated tau-related
neuron skeletal hypothesis; we also comment on the systemic theories that emphasize
the fetal origin of the complex disorders that include the low inflammatory and immu-
nity theories of sAD.
New/updated hypothesis: Lf has important anti-infectious and immunomodulatory
roles in health and disease. We present the hypothesis that the reduced levels of saliva
Lf could be an effect of immunological disturbances associated to sAD. Under this sce-
nario, two alternative pathways are possible: first, whether sADcould be a systemic dis-
order (or disorders) related to early immunological and low inflammatory alterations;
second, if systemic immunity alterations of sAD manifestations could be downstream
of early sAD brain affectations.
Major challenges for the hypothesis: The major challenge of the Lf as early sAD
biomarker would be its validation in other clinical and population-based studies. It is
possible the decreased salivary Lf in early sAD could be related to immunological mod-
ulation actions, but other different unknown mechanisms could be the origin of such
reduction.
Linkage toothermajor theories:This hypothesis is in agreementwith twophysiopatho-
logical explanations of the sAD as a downstream process determined by the early
lesions of the hypothalamus and autonomic vegetative system (neurodegeneration), or
as a consequence of low neuroinflammation and dysimmunity since the early life aggra-
vated in the elderly (immunosenescence).
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
c○ 2020 The Authors. Alzheimer’s & Dementia published byWiley Periodicals LLC on behalf of Alzheimer’s Association
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1 OBJECTIVE
Here we aimed to discuss the hypotheses that low salivary lactoferrin
(Lf) reflects dysfunctions in the immune system in sporadic Alzheimer’s
disease (sAD). These immunity alterations could be secondary to the
early hypothalamic lesions within the neurodegenerative process, or
a primary systemic disorder related to early immunological and low
inflammatory alterations mainly involving the brain. The second alter-
native cannot be discarded, but the former seems more comprehensi-
ble and supported by the evidence.
Wewill analyze if sAD biomarkers and particularly salivary Lf could
mirror systemic sAD alterations. Brain resilience masks the classical
brain burden of protein aggregates hindering the detection of AD
pathology at early stages through detection of such aggregates. Cur-
rently used preclinical biomarkers such as amyloid beta (A𝛽) and tau
levels in cerebrospinal fluid (CSF) and neuroimaging do not have high
prediction validity in clinical series and are expensive and invasive.
Therefore, we think that the evaluation of sAD biomarkers, such as Lf,
could be a new pathway to explore.
2 BACKGROUND
2.1 Historical evolution
Genetic studies in the last century determined a clear distinction
between familiar Alzheimer’s disease (fAD) caused by mutations in
three well-known genes and sAD, in which genetic, epigenetic, and
environmental interplay may determine the phenotype of disease.2,3
fAD is commonly presented with early clinical manifestations (<5% of
the AD cases) while sAD is presented with late clinical manifestations
representing the majority of cases (>95% of AD cases).2,3 In the evo-
lution of AD research, predementia state definition as mild cognitive
impairment (MCI) was considered a hot spot. This helped to focus the
research on biomarkers in the last decade to detect sAD in early pro-
dromic stages. It is important to detect the earlymanifestations of sAD
by specific biomarkers to prevent the evolution of the predementia-
possible sAD to an established sAD-dementia, in which no therapy is
able to modify its fatal evolution. An increasing number of new drugs
are under investigation; also, lifestyle modifications are in surveillance
to accomplish this objective.2 But, it is becoming clear that the main
classical pathophysiological lesions, the folded brain proteins accumu-
lation (tau and A𝛽), detected by anymethod (blood, saliva, CSF, or neu-
roimaging) are not reliable enough for the diagnosis of this predemen-
tia phase of sADwith precision. The brain resilience to the sAD lesions
over decades and the complicated detection of brain lesions impeach
the early detection of the predementia phase with sufficient clinical
confidence. Therefore, sAD, included in its early phases, generates sev-
eral systemic body changes (skin, blood, plasma, cells, saliva, etc.)4 that
could determine biomarkers that possibly allow the sAD initial diagno-
sis more easily and cheaply, andwith higher confidence.
In this scenario, we describe that saliva Lf could be an early
biomarker for sAD.1 This discovery, in some way serendipitous, is
biologically funded. For this explanation we will first describe very
briefly the “state of the art” of sAD biological causation and patho-
physiology.
sAD is a complex disorder caused by the interplay of several genetic
risk alleles (≈ 20), epigenetic modifications, and multiple environmen-
tal factors along with aging.2 Among the genetic risk, apolipoprotein
E𝜀4(APOE 𝜀4) could be prominent in the majority of ethnic groups
accompanied by≈ 20 risk alleles (there are also 3 protective alleles).2,3
The best twin study estimates approximately 50% genetic risk,5 which
is greater than the genetic risk assumed by genome-wide association
study (GWAS) and future sophisticated genetic studies may identify
additional hidden genetic risk. This situation and the brain neurons’
genetic mosaicism that may contribute to sAD6 preclude the use of
genetic evaluation as a sAD biomarker tool, apart from APOE 𝜀4, in
the diagnosis of sAD.Many studies demonstrated that early epigenetic
(soft heredity) clues, includingDNAmethylation or demethylation, his-
tone modifications, and non-coding RNAs, may modify the DNA (hard
heredity) and the risk for sAD. To our knowledge, only one study to
the date of the present publication, quantifies such sAD risk conclud-
ing that this risk is modest.7
Hundreds of environmental, individual circumstances have been
evaluated as modifiable risk/protective factor for sAD.8 This risk con-
tribution to sAD has been estimated between 30% to 66% in several
studies.2,8 It is apparent that these environmental factors have a clin-
ical diagnostic importance but have no biomarker utility. The impor-
tanceof environmental factors is clear,with theevidence in the last two
decades of the decrease of sAD incidence in affluent countries.2,9
A very brief summary of the pathophysiology of sAD seems is
important. The most credited pathophysiology of sAD in the last three
decades is the “amyloid cascade hypothesis,” determined by analogy
from the genetic errors in familial AD, but in the last decade this
theory has increasingly been discarded mainly due to the negative
results of anti-amyloid trials and the previously unknown biochemical
role of this protein.2,10 However, it has been recently demonstrated
that there is another possible role of A𝛽 in the sAD physiopathology.
A𝛽 is a highly conserved effector molecule in innate immunity and
its role in sAD could be due to its antimicrobial action as proposed
in the antimicrobial protection hypothesis.11 The amyloid cascade
hypothesis blurred the fact that phosphorylated tau deposition is the
first lesion of AD type observed in normal brains since early childhood,
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as demonstrated in different studies.12,13 These works showed that
several decades prior to allocortex phosphorylated tau deposition in
the locus coeruleus and other brain stem nuclei interconnected with
the allocortical entorhinal and transentorhinal regions showed accu-
mulated pre-tangles representing early sAD tau-related cytoskeletal
alterations. Although the basic molecular mechanisms of sAD are not
known, many authors accept that the degenerative process of the
AD-related cytoskeletal pathology follows the anatomical pathways
for its brain propagation initiated in brain stem nuclei that could lead
transneuronally to the specific brain distribution pattern of tau pathol-
ogy. This is in agreement with the hypothesis showing sAD as a chronic
prion-like neurodegenerative disease. This more recent tau hypoth-
esis explanation for sAD, gives the opportunity to find long-term
preventive strategies (drugs or lifestyle modifications) as represented
in Figure 1.
These two etiological hypotheses are the most accepted, but
there are many others: the initial hypothesis of cerebral vascular
hypoperfusion in sAD has been updated.10,14 In addition, the popular
“excessive aging” explanation for this disorder has supporters with
well based scientific background;15 Terry’s “synaptic deficit”; and the
“two hit hypothesis” (abnormal neuronal cell cycle re-entry mitosis)
due to oxidative stress or to other biological abnormalities have
elicited many comments.2,14-17 Apart from these hypotheses related
to brain cell conformations there are others with more systemic
underpinnings such as early fetal (or infant) stress due to inappropriate
nutrition, toxins, or metabolic or infectious causes that support the
Development Origin of Health and Disease (DOHaD) postulates of
non-transmissible disorders such as neurodegenerative disorders
(NDD), including sAD.2,17 There are more systemic-based explana-
tions for sAD risk based on metabolic derangements (mitochondrial
oxidative stress) and metal action aberrations (calcium, aluminium,
etc.).2,6,14,16 None of these last mentioned hypotheses have been
widely accepted. More recently, new hypotheses that implicate the
gut-brain axis or infectious agents2,11,14,16 have had wide diffusion.
These two hypotheses involve brain-immunity relationships. Micro-
biota in the gut have immune system development functions, and
anti-infectious actions forming a biotic shield between our body and
the outside world, but may contribute to low-grade inflammation
progress.2 The infections and immunity activations have an increasing
role as sAD risk factors in the literature.11,18
2.2 Rationale
The immunological (and low inflammatory) alterations in sAD and in
other NDD are well known.19 The origin and intensity of these mod-
ifications attributed to sAD could be diverse. There are works indi-
cating that early in the central nervous system (CNS) development,
genetic and epigenetic modifications occur, and they are related to
the immunological hypothesis.18,20 Other authors suggest immuno-
logical derangements as contributing factors to the development of
sAD21 and there are other groups that consider that the immuno-
logical aberrations in sAD could be a secondary downstream phe-
RESEARCH INCONTEXT
1. Systematic review: We searched in PubMed for arti-
cles published in English up to November 2019 with the
terms “Alzheimer’s biomarkers”, “peripheral biomarkers”,
“saliva proteins”, “saliva function”, “preclinical Alzheimer”,
“Alzheimerprediction”, “lactoferrin”, “infections”, “immune
system”, among others. In recent years, there have been
intensified efforts in searching minimum or non-invasive
peripheral markers for the early diagnosis of AD, focused
on blood and/or saliva. Findings have shown the associ-
ation between AD and immune system, including virus,
bacteria and yeast infections, which is associated with an
increase inflammatory response. Moreover, it has been
proposed that brain infections may be involved in the
development of AD. The dissemination of oral microor-
ganisms to the brain is controlled by antimicrobial pep-
tides, as part of the innate immune system. In the last
decade, several studies have explored the role of these
antimicrobial peptides as potential biomarkers for AD. In
2017, we showed that salivary lactoferrin (Lf) discrimi-
nates between patients with mild cognitive impairment
(MCI) and AD and control subjects.
2. Interpretation: Findings from the main pathophysiolog-
ical theories of sAD were reviewed here proposing the
hypothesis that the reduced levels of salivary Lf could
be related to immunological disturbances associated to
sAD. This hypothesis is in agreement with two phys-
iopathological explanations of the sAD as a downstream
process determined by the early lesions of the hypotha-
lamus and autonomic vegetative system (neurodegenera-
tion), or as a consequence of low neuroinflammation and
dysimmunity since the early life aggravated in the elderly
(immunosenescence).
3. Future direction: Future work should confirm our results
in other clinical cohorts and/or population-based studies.
This alternative theory of the sAD genesis needs more
observational and experimental data to get a comprehen-
sive understanding of the relationships between the ner-
vous system and the immune system.
nomenon to brain lesions.22 Recently, several authors have stressed
that these immunological derangements are more accentuated dur-
ing aging,23,24 strengthen aging as the main risk factor of sAD.15 In
this scenario of relationships between sAD and a patient’s immuno-
logical status, it is rational that a saliva component such as Lf,
which has anti-infectious and immunomodulatory functions, could
be a biomarker of the immunological state of sAD,1 as we will
discuss.
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F IGURE 1 Alzheimer’s disease (AD) evolution. Presymtomatic, preclinical, and clinical periods. The diagram shows the evolution of a
hypothetical AD case. The AD pathologic burden (neurofibrillary tangles and senile plaques) is represented in a rising line. The top of the figure
express the AD evolution periods. The long preclinical period can be divided into pre-symptomatic (only histological alterations) and true
preclinical (positive AD biomarkers in cerebrospinal fluid or neuroimaging, without clinical manifestations). The AD clinical period is divided in the
predementia state mild cognitive impairment (MCI) (gray stripe) and in the clinical dementia period. The years depictedmust be considered
standard ranges; moreover, the presymptomatic period could be probably>40 years in some cases, and the sporadic Alzheimer’s disease dementia
period could be from 3months to 20 years. Taken fromBermejo-Pareja, 2018 [2] withminor modifications
3 UPDATED HYPOTHESIS
3.1 Early experimental or observational data
sAD is associated with early systemic alterations including immuno-
logical status. Two possible explanations could describe the observed
immunological and low inflammatory alterations in sAD: First, an
immunological “causal” explanation for sAD, by which nervous system
development could be affected by early immunological deregulations
and this would be maintained during the lifetime in a “low inflamma-
tory state.” When aging the low inflammatory state would become
higher and this would determine the sAD phenotype.18,20 The sec-
ond alternative would propose immunological alterations as a sec-
ondary downstream phenomenon caused by early affectations of the
autonomous (or vegetative) nervous system regulating immunological
system.22,25,26 Then, a third, combined explanation could also be con-
sidered by which there are some connections between the other two
proposed27 or a network between the nervous systemand the immune
system.28
3.1.1 Nervous system and immune system
interactions
Previous dogma considered the nervous system and immune system as
autonomous entities, but now the immune system is conceptualised as
an integrated entity within the nervous system as both systems work
in coordination in host defense or even other sensory structures of
the brain.28 Many authors suggest that the relationships between the
two systems are bidirectional, very complex, but far from completely
understood.26-28 The tight communications between nervous system
and immune system appear early in the evolution. The C. elegans ele-
mental nervous system (302 neurons) includes a network of neurons
able to aid and control the immunity of this invertebrate.29 Segner et
al reviewed the nervous system (hypothalamus-hypopituitary repro-
ductive axis)–immune system exchange in vertebrate evolution.30
From this review it seems clear that the immune system is regulated
by the nervous system along the evolution involving all cells related
to innate immunity: eg, macrophage, natural killer (NK) cells, and den-
dritic cells (antigen-presenting cells) that bridge innate and adaptive
immune cells, and the adaptive immunity (T and B lymphocytes) that
upon exposure to antigens act as specific immunity.22,30 The relation
between nervous system-immune system may be explained as a bidi-
rectional interaction, as most brain cells (neurons and glial cells) have
receptors to cytokines produced by immune cells, and simultaneously
immune cells have receptors to neuropeptides, neurotransmitters, and
neurohormones, suggesting a common ancestral origin.31
The nervous system control is clearly delineated at local, regional,
and general levels in humans.22,26 This regulation is locally performed
by the “axon reflex,” which could be pro-inflammatory ormitigating the
inflammation. At regional and systemic levels, such regulation ismainly
made by the autonomous nervous system, which controls all basic veg-
etative functions excluding the general muscular system.32 This con-
trol is conductedby the sympathetic andparasympathetic (vagal nerve)
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F IGURE 2 Interactions and regulation of
nervous and immune systems. This diagram
represents the close interaction between the
nervous and immune system. The nervous system
hasmany afferences from the immune system: by
immune system transmitters: cytokines, peptides,
and others, including immune cells (fine lines); the
immune cells and their transmitters acceded to
nervous system trespassing the blood-brain barrier
by circumventricular organs, capillary diapedesis,
and cerebrospinal fluid inter-neuronal-glial space;
and by nervous impulses via sensory neurons
(spinothalamic tract) and peripheral nervous
system, autonomous nervous system included (fine
open arrow at left bottom). Themain effectors of
the nervous system to immune system are
hypothalamic hormones (mainly by the
hypothalamic-pituitary adrenal axis), and
peripheral nervous system (PNS), but also
neurotransmitters (descending open bold arrows).
Scheme designedwith datamainly from references
[22] and [25]. Other more complex explanations
[28] are not represented
that could be considered the immune system control “hardwiring,” and
by neurohormones through the hypothalamic-pituitary adrenal (HPA)
axis and by neurotransmitters. In general, the nervous system activity
promotes the immune system modulation until a homeostatic stable
state is obtained.26,28
Recently, it has been considered that the third revolution in
immunological thinking is the integration role of neurological feed-
back circuits that regulate the immune system. Axonal reflex is the
most simplex determined by the local sensorial neurons without ini-
tial participation of the CNS. More complex is the reflex determined
by autonomous nervous system (sympathetic, parasympathetic—vagal
nerve- and enteric parts) integrated in the spinal cord (sympathetic
nervous system) and in the brain stem (parasympathetic).22 The affer-
ent part of these reflexes is established at the local level by the
sensorial neurons that sends its branches across the spinothalamic
way to the brain stem (medullar and mesencephalon nuclei and net-
work structures) reaching the thalamus. Brain stem structures also
receive information from the autonomous nervous system (80% of
the vagal nerve is sensorial) regulating basic functions (respiration,
the heart, sleep, and immunity). Moreover, it has been suggested that
the immunity function could be additionally integrated in the cor-
tex conforming an “immunological homunculus,” with reminiscences
from the sensory or motor cortical homunculus22 (Figure 2). Efferent
response in the CNS comes after a complex integration in the subcor-
tical structures (brain stem structures, hypothalamus, and other parts
of the limbic system), several thalamic nuclei, and the cortex. Sympa-
thetic and parasympathetic systems (vagal nerve), the HPA hormones,
and neurotransmitters mediate the efferent nervous system response.
Also, it is well known that the vagal reflex or “inflammatory reflex,” a
vagal nerve action (acetylcholine neurotransmission to the immunity
cells of the spleen) in a complex interaction with the noradrenergic
transmission and lymphocyte neurotransmitters, suppressing exces-
sive inflammation.26 Along the way, Besedovsky considered that the
immune system actually works as a sensory system integratedwith the
other sensory systems (touch, sight, etc) of the nervous system where
not only participate as neuron to neuron synapses but also astrocytes
(“tripartite synapsis”) and possibly microglia.28
Summarizing, the nervous system decreases immune system over-
reaction to body insults (pathogens and other stressful situations), try-
ing to re-establish homeostasis. Locally, sensory neurons could poten-
tiate, or at leastmodulate, general immune reactions.26,28 Figure 2 fur-
ther represents the nervous system and immune system interactions.
3.1.2 Sporadic Alzheimer’s disease (sAD) preclinical
periods
The cognitive decline in AD (familial and sporadic) is very slow, and in
most patients is preceded by a clinical predementia state or preclinical
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sAD. This is known thanks to several survey studies such as the
Framingham cohort and other European studies (ie, PAQUID study),
which have demonstrated a long preclinical and very subtle cognitive
decline. These cognitive changes were only detected in psychometric
tests but not by the participants or their relatives. Later on, cognitive
decline became apparent and turned to clear MCI or classical AD
dementia prior to any clinical appearance.2 Also, in the last decade
of the 20th century, a descriptive pathological data study carried out
on a German brain bank confirmed the slow tau neuron skeletal brain
alterations above mentioned.12 The study estimated the evolution of
sAD Braak stages in about 16 years from stage I to stage II and around
14 years from stage II to stage III, when the first manifestations of
cognitive deterioration appear.12 Therefore, the most characteristic
sAD pathological lesions evolve slowly over decades, in agreement
with the clinical observations of subtle memory deterioration decades
before the appearance of sAD. More recently, neuroimaging methods
corroborated the clinical silent period of tau andA𝛽 deposition prior to
the clinical appearance of sAD33 (Figure 1). The preclinical periodwith-
out clear cognitive decrease usually precedes a predementia period
sAD. This period had several denominations, but the most commonly
utilized was Petersen’s MCI, considered an initial stage of AD. Later, it
has been demonstrated that MCI could be a precursor of other types
of dementia: neurodegenerative diseases (NDD), cerebrovascular, and
psychiatric affections, including depression and others.34 Conclusions
from an international working group in a key symposium celebrated in
2003 in Stockholm clearly defined MCI and established different sub-
types including the amnesic type, the most frequent form of MCI to be
converted into AD.34,35 In the last decade, intensive biomarker studies
using CSF and neuroimaging data tried to detect the asymptomatic
and MCI phases and established complex definitions of this period
prior to sAD.36 That resulted from thework of two recognized interna-
tional groups: the National Institute on Aging/Alzheimer Association
(NIA-AA) and the International Working Group for New Research
Criteria for the Diagnosis of AD. They have continuously revised
several definitions of preclinical AD to perform treatment trials in
cognitively asymptomatic people.36 All these definitions are based on
clinical series. The last definition of theNIA-AAcameout in the “biolog-
ical Alzheimer’s” researchwork only based on biomarkers of A𝛽 (senile
plaques) and tau (neurofibrillary tangles) but not on clinical data. In
the last study using a cohort from the Mayo Clinic population-based
registry, it was stated the biological Alzheimer’s is overwhelmingly
more frequently than the traditional clinically diagnosed sAD. The last
prevalence study (three times more in 85-year-old people) has shown
the discrepancy between the complex “biological definition” of AD and
its traditional clinical diagnosis.37
In summary, in the last two decades, strong evidences has shown
that most of sAD cases have a long pre-symptomatic evolution prior to
clinical (MCI or dementia) beginning. A simple scheme of this evolution
is shown in Figure 1.
3.1.3 Are there data of immunological alterations
along the sAD preclinical periods?
Support for the immunological-inflammatory cause of sAD is contro-
versial. It is true that long ingestion of anti-inflammatorymedications is
associatedwith low risk of sAD, including sADmortality data,38 but the
anti-inflammatory trials have produced negative results.39 Contrarily,
it is known that Down syndrome patients, considered a biological AD
model, have a long-standing decrease in their immunological status
supporting the relationship between immunity and sAD.40
3.1.4 Sporadic Alzheimer’s diseases (sAD) and the
predementia period, inflammatory and immunological
deficits, hypothalamic and limbic lesions
It is not clear that behavioral abnormalities including irritability and
depression are precognitive sAD manifestations but a decrease in the
bodymass index (BMI) and/or sleep disorders may clearly appear prior
to any clinical symptoms of cognitive decline.
BMI and sleep alterations might indicate hypothalamic deficits.41
Several sleepwaking alterations have been described in sAD. There are
many explanations for these findings described in sAD. Baloyannis et al
demonstrated in early-onsetADcases that several hypothalamic nuclei
(suprachiasmatic, supraoptic, and paraventricular) showed pathologi-
cal hallmarks including reduced neuronal population, dystrophic axons,
abnormal Golgi, and synaptic spines without the characteristic AD
pathology (neurofibrillary tangles and senile plaques) in these areas.42
These alterations were present in the hypothalamus of brains from 12
sAD patients with clear sAD clinical pathological diagnosis suggest-
ing that these morphological hypothalamic neuron alterations could
appear very early inADprior toA𝛽 and tau deposition.12 Many authors
recognize the hypothalamus as the most important autonomous ner-
vous systemengine, but others includedother limbic structures such as
thehippocampus.27,32 Nevertheless, themost clinically detectable pre-
cognitive characteristics in AD, BMI decline and sleep alterations, are
mainly due to hypothalamic dysfunctions and appear years before cog-
nitive decline. BMI is commonly reduced in older adults, but a number
of studies have shown thatmany years before clinical cognitive decline,
sAD patients reported a BMI decline higher than the non-sAD con-
trols in community- and hospital-based clinical series.41 Similar find-
ings were observed in preclinical dominant genetic AD where weight
decline began one or two decades before clinical AD appearance.43
Therefore, the origin of these two clinical alterations, BMI and sleep
quality, is not well known but the existing data indicate alterations in
hypothalamic and limbic structures that may be included as AD pre-
cognitive defects, suggest that functions of these brain structures (ie,
systemic immunity control), could be affected in this disease at early
stages.22,32,41
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3.1.5 Hypothalamic dysfunctions in sADmay
preclude immunity alterations, including salivary
lactoferrin
It is well known that sAD evolution is associated with several immu-
nity deficits, although some of them are only evident in late stages of
disease.23,24 These impairments may occur during the sAD preclinical
stage and probably they facilitate sAD progression according to exper-
imental and clinical findings.21 Many authors suggest that immune
system disturbances associated to sAD may be consequences of ner-
vous systemdysfunctiondeterminedbyhypothalamic lesions.22,27 This
opinion is supported by experimental evidence using injured and/or
stimulated animal models and probably is based on limbic system
lesions (hippocampus, hypothalamus, and several brain stem nuclei),
which represents a primitive hub controlling body functions regulated
by the autonomous nervous system.27,32,41,42 The hypothalamus inte-
grates the majority of basic life functions: energy metabolism (feed-
ing); fluid and electrolyte balance (drinking); thermoregulation, fever
responses; wake-sleep cycles; emergency response to stressors; repro-
duction (mating, pregnancy, birth);32 and body immunity.25,27,28,30
The integrated functions of nervous and immune systems could
be affected during preclinical and early prodromal sAD, and later on
during MCI and dementia stage of sAD, as hypothalamus and limbic
structures have early AD lesions leading to loss of the nervous system
and immune system homeostasis26,44 (Figure 2). It has been described
that the affected nervous system structures in sAD generate an upreg-
ulation of brain immunity,45 and simultaneously a downregulation of
the systemic immunity. The elderly decline in systemic immunity, now
called “immunosenescency,” is frequently observed in humans23,24 and
animals,46 but its origin is controversial. It is probably associated with
hypothalamic functional decay as reported in experimental and human
data.23
In this scenario, we are interested in Lf. Lf is the main protein com-
ponent in saliva. Lf is a highly conserved polypeptide chain (glycopro-
tein) contained in most mammalian exocrine secretions as milk, saliva,
and tears, and also is found in blood neutrophils. Lf is a pleiotropic pro-
tein that could be considered the first line for defense against infec-
tions, including periodontal bacteria, and has several immunological
properties (see Table 1).47-49 Saliva is an easily accessible physiological
fluid that can be collected in a non-invasive way. It is well known that
saliva has many physiological functions and its protein composition
lendsmany anti-infections and immunological properties. Because sali-
vary Lf decrease appears early in the sAD development1, perhaps due
to the early hypothalamic immunity dysregulation in sAD, we propose
that Lf could be downregulated in sAD as other aspects of systemic
immunity in sAD. For that reason, Lf may be a good biomarker candi-
date for initial and clinically established sAD.1 However, further stud-
ies are needed to clarify several unresolved questions of importance
for being a good sADbiomarker; for example, the fact that Lf is reduced
in salivary secretions in AD cases and such reduction is not observed in
Parkinson’s disease (PD).1 AlthoughPD is aNDDaffecting autonomous
nervous system and several brain stem structures, PD alterations do
TABLE 1 Main physiological actions of Lactoferrin
Physiological actions Mechanisms
Iron-binding protein Iron absorption, transport and sequestration
Host defence Activities against pathogens: antibacterial,
antifungal, antiparasitic, antiviral
Anti-inflammatory and alarming
Anti-endotoxin
Anticancer
Inhibition of prion accumulation
Host activities Brain development and neuroprotection: alleviating
psychological stress
Bone formation
Gastrointestinal development
Immune actions (innate and adaptive): enhancer
andmodulator
Wound healing
Metabolic Adipocytes differentiation
Antioxidant: inhibiting lipid peroxidation
Association with other proteins: osteopontin and
others
Decreasing vasoconstriction
Enzymatic activities
Glucose regulation (decreasing hyperglycemia)
Gut microbiota modulation
Transcriptional regulator
Miscellaneous Compounds or metabolites carrier (mainly into
brain)
Vaccine adjuvant
Possible sAD biomarker
not compromise the same hypothalamic and limbic system structures
that are affected in sAD. Moreover, in PD brains main lesions affect
early only the mesencephalic dopaminergic neurons.50 Alternatively,
we pointed out that the deficiency of salivary Lf in sADmight facilitate
oral bacterial or viral proliferation, inducing periodontal infections, and
the expansion of pathogens or their inflammatory products to the ner-
vous system; therefore, it could be a risk factor for sAD.49
3.2 Future experiments and validation studies
It would be desirable to determine whether the reported reduction of
salivary Lf levels in sAD in our study will be confirmed in new research
and particularly in population-based studies. Our published study was
carried out using MCI and AD cases clinically evaluated compared to
healthy age-matched controls; therefore, we consider it would be rel-
evant to determine Lf levels in population-based elderly cohorts to
obtain more unbiased results. It will be useful to study the specificity
of salivary Lf decrease in sAD, by analyzing the levels of this protein in
other NDD such as PD and frontotemporal dementia (FTD). We con-
sider these analyses very important because these two NDD are the
main differential diagnostic entities from sAD. It is possible salivary Lf
levels in these two NDD other than sAD remain unchanged compared
to healthy subjects as brain structures in these diseases are different
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from those in AD:mesencephalic dopaminergic neurons in PD and cor-
tical structures in FTD. In linewith the specificity determination of sali-
vary Lf, compared to other dementias, it would also be important to
analyze salivary Lf in “pure” vascular dementia. On the other hand, sali-
vary Lf determination in genetic AD and Down syndrome cases would
also be important to fulfil the salivary Lf evaluation. Additionally, inves-
tigation of salivary Lf regulation and function in experimental animals
(transgenic mice) carrying the human genetic ADmutations could con-
firm the early affectation.
4 MAJOR CHALLENGES FOR THE
HYPOTHESIS
The major challenge of the Lf hypothesis as early biomarker of sAD
is the confirmation of our results in other clinical cohorts and/or
population-based studies. The utility of Lf salivary determination in the
elderly is basedonour very gooddiagnostic capacity of Lf in early phase
of clinical sAD (MCI and clinical apparent sAD dementia). It would be
necessary to discard the reduction of salivary Lf levels as consequence
of unknown mechanisms other than related to immunological mod-
ulation. Confirmation of our hypothesis would determine salivary Lf
would be an easy and cheap biomarker that could be included in the
biomarker’s armamentarium of sAD.
5 LINKAGE TO OTHER MAJOR THEORIES
This hypothesis could be in agreement with the most accepted patho-
physiological views of sAD. Salivary Lf decrease could be a down-
stream phenomenon consequence of early hypothalamic lesions and
autonomous nervous system dysfunction in sAD.22,27,32,44 The alter-
native hypothesis, the great pathophysiological importance of early
low neuroinflammation and immunity impairments in the genesis and
risk prolongation of sAD18,20 that could be aggravated in the very
elderly (“inflamm-aging”)23,24 adequately coupled with our findings.
Our study agrees with the hypothesis that immune alterations and
brain infections might play an initial role in the development of AD
pathology. In this context, antimicrobial peptides, such as Lf, may con-
trol this dissemination to the brain. Thus, salivary Lf reduction may
represent a reduced oral protection, exacerbating the risk of AD. It is
obvious that in our opinion this alternative theory of the sAD genesis
needs more observational and experimental data to overcome the tra-
ditional clinical-pathological explanation of the sAD phenotype. More-
over, both explanations could interplay to explain our findings because
the relationships between the nervous system and the immune system
are tight and bidirectional.27,28
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